Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib with Gemcitabine and Cisplatin in Advanced Urothelial Carcinoma
NCT00246974Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2003
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gefitinib in transitional cell carcinoma of the urothelium (TCC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Time to progression. Started May 2003; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma of the urothelium (TCC)
Beyond the preview
Go deeper on NCT00246974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00246974.